Nkarta (NKTX) Competitors $1.83 +0.01 (+0.55%) Closing price 04:00 PM EasternExtended Trading$1.83 0.00 (0.00%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. VALN, BCAX, PGEN, SIGA, ATYR, ORKA, CAPR, CGEM, MREO, and KMDAShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Valneva (VALN), Bicara Therapeutics (BCAX), Precigen (PGEN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Oruka Therapeutics (ORKA), Capricor Therapeutics (CAPR), Cullinan Therapeutics (CGEM), Mereo BioPharma Group (MREO), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors Valneva Bicara Therapeutics Precigen Siga Technologies aTyr Pharma Oruka Therapeutics Capricor Therapeutics Cullinan Therapeutics Mereo BioPharma Group Kamada Valneva (NASDAQ:VALN) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Is VALN or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Valneva's net margin of -43.08%. Nkarta's return on equity of -26.64% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-43.08% -43.05% -16.23% Nkarta N/A -26.64%-21.62% Do institutionals and insiders hold more shares of VALN or NKTX? 11.4% of Valneva shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 8.4% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor VALN or NKTX? In the previous week, Valneva had 3 more articles in the media than Nkarta. MarketBeat recorded 5 mentions for Valneva and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.22 beat Valneva's score of 0.78 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, VALN or NKTX? Valneva has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Do analysts prefer VALN or NKTX? Valneva currently has a consensus target price of $15.50, suggesting a potential upside of 139.05%. Nkarta has a consensus target price of $14.33, suggesting a potential upside of 683.24%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Which has stronger earnings & valuation, VALN or NKTX? Valneva has higher revenue and earnings than Nkarta. Valneva is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$183.52M3.01-$13.25M-$1.19-5.45NkartaN/AN/A-$108.79M-$1.51-1.21 SummaryNkarta beats Valneva on 9 of the 16 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.85M$2.93B$5.57B$9.32BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-1.2120.5028.6419.75Price / SalesN/A267.15432.34182.50Price / CashN/A43.1536.0257.96Price / Book0.327.768.235.67Net Income-$108.79M-$55.11M$3.24B$257.98M7 Day Performance1.10%1.03%0.05%0.56%1 Month Performance-3.17%8.54%5.65%8.88%1 Year Performance-77.13%-2.26%26.57%14.24% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta1.8172 of 5 stars$1.83+0.5%$14.33+683.2%-74.1%$129.85MN/A-1.21140Positive NewsVALNValneva1.7985 of 5 stars$5.75-1.0%$15.50+169.6%-12.8%$494.40M$183.52M-4.83700Gap DownBCAXBicara TherapeuticsN/A$9.01-0.2%$31.86+253.6%N/A$492.46MN/A0.0032PGENPrecigen4.0427 of 5 stars$1.59-1.9%$6.00+277.4%+12.5%$478.19M$3.92M-2.84190News CoveragePositive NewsAnalyst RevisionSIGASiga Technologies2.2222 of 5 stars$6.73+0.6%N/A-26.6%$477.94M$138.72M10.0440News CoverageATYRaTyr Pharma2.0541 of 5 stars$5.30-0.2%$20.20+281.1%+219.0%$472.61M$230K-6.5453Gap DownHigh Trading VolumeORKAOruka Therapeutics2.929 of 5 stars$13.29+5.5%$40.38+203.8%N/A$471.75MN/A-2.95N/ANews CoveragePositive NewsCAPRCapricor Therapeutics2.5262 of 5 stars$9.90-3.4%$32.22+225.5%+54.1%$468.19M$22.27M-6.97101Analyst ForecastAnalyst RevisionGap UpCGEMCullinan Therapeutics1.7321 of 5 stars$7.42-5.0%$30.00+304.3%-55.1%$460.90MN/A-2.5530News CoverageMREOMereo BioPharma Group1.5646 of 5 stars$2.92+1.7%$7.60+160.3%-58.8%$456.33M$10M-41.7140High Trading VolumeKMDAKamada4.3052 of 5 stars$7.71-2.2%$13.00+68.6%+30.8%$453.14M$160.95M26.59360 Related Companies and Tools Related Companies Valneva Competitors Bicara Therapeutics Competitors Precigen Competitors Siga Technologies Competitors aTyr Pharma Competitors Oruka Therapeutics Competitors Capricor Therapeutics Competitors Cullinan Therapeutics Competitors Mereo BioPharma Group Competitors Kamada Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
